Significance of factors in the detection of mutations
Factor . | No. of patients . | Total no. with mutations (%) . | P . |
|---|---|---|---|
| Time from diagnosis to imatinib start | < .0001 | ||
| Less than 1 y | 46 | 0 | |
| 1-2 y | 26 | 4 (15) | |
| More than 2 y to 4 y | 28 | 5 (18) | |
| More than 4 y | 44 | 18 (41) | |
| Disease phase at imatinib start | |||
| Early-CP. | 40 | 0 | .0039 |
| Late-CP | 64 | 14 (22) | |
| Early-CP | 40 | 0 | |
| AP | 40 | 13 (33) | .0003 |
| Late-CP | 64 | 14 (22) | |
| AP | 40 | 13 (33) | .3308 |
| Clonal evolution in AP patients | |||
| No clonal evolution | 19 | 5 (26) | |
| Clonal evolution | 21 | 8 (38) | .6482 |
| Cytogenetic response at 6 mo | |||
| MCR | 94 | 8 (8.5) | <.0001 |
| No MCR | 50 | 19 (38) |
Factor . | No. of patients . | Total no. with mutations (%) . | P . |
|---|---|---|---|
| Time from diagnosis to imatinib start | < .0001 | ||
| Less than 1 y | 46 | 0 | |
| 1-2 y | 26 | 4 (15) | |
| More than 2 y to 4 y | 28 | 5 (18) | |
| More than 4 y | 44 | 18 (41) | |
| Disease phase at imatinib start | |||
| Early-CP. | 40 | 0 | .0039 |
| Late-CP | 64 | 14 (22) | |
| Early-CP | 40 | 0 | |
| AP | 40 | 13 (33) | .0003 |
| Late-CP | 64 | 14 (22) | |
| AP | 40 | 13 (33) | .3308 |
| Clonal evolution in AP patients | |||
| No clonal evolution | 19 | 5 (26) | |
| Clonal evolution | 21 | 8 (38) | .6482 |
| Cytogenetic response at 6 mo | |||
| MCR | 94 | 8 (8.5) | <.0001 |
| No MCR | 50 | 19 (38) |